Expert feedback highlighted missing information about dosages and administration routes in certain responses (a misassociation where the model incorrectly linked insulin use to prediabetes despite a type 2 diabetes diagnosis) and instances where rare side effects were inaccurately reported as common. This evidence concerns the gene INS and type 2 diabetes mellitus.